DelveInsight’s “Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as the Atypical Hemolytic Uremic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Atypical Hemolytic Uremic Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Atypical Hemolytic Uremic Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atypical Hemolytic Uremic Syndrome Market Insights
Some of the key facts of the Atypical Hemolytic Uremic Syndrome Market Report:
-
Atypical Hemolytic Uremic Syndrome market is expected to grow significantly owing to an increase in upcoming novel treatment options, increasing market size due to improved survival and increasing awareness of Atypical Hemolytic Uremic Syndrome (aHUS)
-
In December 2023, A group of five experts from Spain has developed consensus guidelines for the management of atypical hemolytic uremic syndrome (aHUS) in adults. These recommendations provide comprehensive guidance throughout the patient’s treatment process, offering support to physicians, particularly those with limited experience, from the initial suspicion of the condition to the commencement and cessation of C5 Therapies.
-
In 2023, the diagnosed cases of atypical hemolytic uremic syndrome (aHUS) in the United States were approximately 2,700. It is expected that these cases will rise during the forecast period from 2024 to 2034.
-
In 2023, there was a higher prevalence of atypical hemolytic uremic syndrome (aHUS) cases in adolescents and adults in the US, with approximately 2,200 cases, compared to the pediatric population, which accounted for around 400 cases. It is anticipated that these numbers will increase by 2034.
-
In 2023, approximately 2,600 cases of atypical hemolytic uremic syndrome (aHUS) were treated in the United States.
-
Key Atypical Hemolytic Uremic Syndrome Companies: Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others
-
Key Atypical Hemolytic Uremic Syndrome Therapies: Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, and others
-
As per the National Organization of Rare Disorders (Nord), the Atypical Hemolytic Uremic Syndrome epidemiology based on gender analyzed that in childhood, Atypical Hemolytic Uremic Syndrome (aHUS) affects males and females in equal numbers
Atypical Hemolytic Uremic Syndrome Overview
Atypical hemolytic uremic syndrome (aHUS) is a rare and life-threatening condition characterized by the formation of blood clots in small blood vessels throughout the body, leading to a triad of symptoms: hemolytic anemia (the destruction of red blood cells), thrombocytopenia (a low platelet count), and acute kidney injury (uremia).
Get a Free sample for the Atypical Hemolytic Uremic Syndrome Market Report:
https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market
Atypical Hemolytic Uremic Syndrome Market
The dynamics of the Atypical Hemolytic Uremic Syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
Atypical Hemolytic Uremic Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation:
The Atypical Hemolytic Uremic Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Atypical Hemolytic Uremic Syndrome
-
Prevalent Cases of Atypical Hemolytic Uremic Syndrome by severity
-
Gender-specific Prevalence of Atypical Hemolytic Uremic Syndrome
-
Diagnosed Cases of Episodic and Chronic Atypical Hemolytic Uremic Syndrome
Download the report to understand which factors are driving Atypical Hemolytic Uremic Syndrome epidemiology trends @ Atypical Hemolytic Uremic Syndrome Epidemiological Insights
Atypical Hemolytic Uremic Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atypical Hemolytic Uremic Syndrome market or expected to get launched during the study period. The analysis covers Atypical Hemolytic Uremic Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Atypical Hemolytic Uremic Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
To know more about Atypical Hemolytic Uremic Syndrome treatment, visit @ Atypical Hemolytic Uremic Syndrome Medications
Atypical Hemolytic Uremic Syndrome Therapies and Key Companies
-
Eculizumab: Alexion Pharmaceuticals
-
Crovalimab: Hoffmann-La Roche
-
Iptacopan: Novartis
-
NM8074: NovelMed Therapeutics
-
Ravulizumab: Alexion Pharmaceuticals
Atypical Hemolytic Uremic Syndrome Market Drivers
-
The introduction of eculizumab in the treatment setting significantly improved the prognosis of aHUS patients.
-
The introduction of ravulizumab in the treatment setting led to a significant reduction of treatment burden, as it provided patients with a treatment option with similar efficacy and safety to that of eculizumab but with a far less frequent dosing frequency.
Atypical Hemolytic Uremic Syndrome Market Barriers
-
The successful launch of iptacopan could significantly improve treatment convenience, as it would bring an oral route of treatment administration in a disease that potentially requires lifelong treatment.
-
Currently, there are limited treatment options for aHUS. Moreover, only a few emerging drugs are active in the pipeline. Thus, it allows pharma players to introduce a novel product candidate into the aHUS market, which can change the therapeutic market scenario.
Scope of the Atypical Hemolytic Uremic Syndrome Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Atypical Hemolytic Uremic Syndrome Companies: Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others
-
Key Atypical Hemolytic Uremic Syndrome Therapies: Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, and others
-
Atypical Hemolytic Uremic Syndrome Therapeutic Assessment: Atypical Hemolytic Uremic Syndrome current marketed and Atypical Hemolytic Uremic Syndrome emerging therapies
-
Atypical Hemolytic Uremic Syndrome Market Dynamics: Atypical Hemolytic Uremic Syndrome market drivers and Atypical Hemolytic Uremic Syndrome market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Atypical Hemolytic Uremic Syndrome Unmet Needs, KOL’s views, Analyst’s views, Atypical Hemolytic Uremic Syndrome Market Access and Reimbursement
Discover more about therapies set to grab major Atypical Hemolytic Uremic Syndrome market share @ Atypical Hemolytic Uremic Syndrome market forecast
Table of Contents
1. Atypical Hemolytic Uremic Syndrome Market Report Introduction
2. Executive Summary for Atypical Hemolytic Uremic Syndrome
3. SWOT analysis of Atypical Hemolytic Uremic Syndrome
4. Atypical Hemolytic Uremic Syndrome Patient Share (%) Overview at a Glance
5. Atypical Hemolytic Uremic Syndrome Market Overview at a Glance
6. Atypical Hemolytic Uremic Syndrome Disease Background and Overview
7. Atypical Hemolytic Uremic Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Atypical Hemolytic Uremic Syndrome
9. Atypical Hemolytic Uremic Syndrome Current Treatment and Medical Practices
10. Atypical Hemolytic Uremic Syndrome Unmet Needs
11. Atypical Hemolytic Uremic Syndrome Emerging Therapies
12. Atypical Hemolytic Uremic Syndrome Market Outlook
13. Country-Wise Atypical Hemolytic Uremic Syndrome Market Analysis (2020–2034)
14. Atypical Hemolytic Uremic Syndrome Market Access and Reimbursement of Therapies
15. Atypical Hemolytic Uremic Syndrome Market Drivers
16. Atypical Hemolytic Uremic Syndrome Market Barriers
17. Atypical Hemolytic Uremic Syndrome Appendix
18. Atypical Hemolytic Uremic Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/